Alcobra Ltd., founded in 2008, is an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. Metadoxine Extended Release (MDX) is the company’s lead investigational product candidate. Alcobra has completed two Phase IIb trials and one Phase III trial of MDX in adults with ADHD. Alcobra has also completed one Phase II adolescent ADHD study of MDX. The company is currently running the MEASURE Study, the second Phase III trial of MDX in adults with ADHD, and expects to report results in mid-2016.
The FDA has granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome. The company has completed one Phase II clinical trial of MDX for the treatment of adolescents and adults with Fragile X Syndrome.
If clinical trials are successful, Alcobra will seek marketing approval for the product from worldwide regulatory bodies including the FDA. Alcobra trades under the symbol “ADHD” on the NASDAQ Global Market and the company completed its initial public offering in 2013. In addition to its headquarters in Tel Aviv, Alcobra has a U.S. office located outside of Philadelphia in Plymouth Meeting, Pennsylvania.